Rich Insights into the Knee Osteoarthritis Clinical Trial

New York, USA, Oct. 31, 2022 (GLOBE NEWSWIRE) — Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight

The prevalence of Knee Osteoarthritis has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of osteoarthritis and the rise in the geriatric population. The Companies developing the potential therapies in the last stage of development include Bone Therapeutics, Biosplice Therapeutics, Levolta Pharmaceuticals, and several others.

DelveInsight’s ‘Knee Osteoarthritis Pipeline Insight – 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline knee osteoarthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the knee osteoarthritis pipeline domain.

Key Takeaways from the Knee Osteoarthritis Pipeline Report

• DelveInsight’s knee osteoarthritis pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for knee osteoarthritis treatment. 
• Key knee osteoarthritis companies such as Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex…